Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters

Rachel M Burckhardt, John J Dennehy, Leo L M Poon, Linda J Saif, Lynn W Enquist, Rachel M Burckhardt, John J Dennehy, Leo L M Poon, Linda J Saif, Lynn W Enquist

Abstract

Waning vaccine-induced immunity coupled with the emergence of SARS-CoV-2 variants has led to increases in breakthrough infections, prompting consideration for vaccine booster doses. Boosters have been reported to be safe and increase SARS-CoV-2-specific neutralizing antibody levels, but how these doses impact the trajectory of the global pandemic and herd immunity is unknown. Information on immunology, epidemiology, and equitable vaccine distribution should be considered when deciding the timing and eligibility for COVID-19 vaccine boosters.

Keywords: COVID-19; SARS-CoV-2; immunity; vaccines.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, Cravioto A, Rees H, Higgins JPT, Boutron I, Pan H, Gruber MF, Arora N, Kazi F, Gaspar R, Swaminathan S, Ryan MJ, Henao-Restrepo AM. 2021. Considerations in boosting COVID-19 vaccine immune responses. Lancet 398:1377–1380. doi:10.1016/S0140-6736(21)02046-8.
    1. Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D, Ostermann PN, Robitzsch R, Hauka S, Walker A, Menne C, Grutza R, Timm J, Adams O, Schaal H. 2021. Age-dependent immune response to the BioNTech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis doi:10.1093/cid/ciab381.
    1. Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O’Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P, mRNA-1273 Study Group. 2021. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med 384:2259–2261. doi:10.1056/NEJMc2103916.
    1. Kertes J, Gez SB, Saciuk Y, Supino-Rosin L, Stein NS, Mizrahi-Reuveni M, Zohar AE. 2021. Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMO. medRxiv doi:10.1101/2021.09.01.21262957.
    1. Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES, mRNA-1273 Study Group, Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott AB, Doria-Rose NA, Arega J, Beigel JH, Buchanan W, Elsafy M, Hoang B, Lampley R, Kolhekar A, Koo H, Luke C, Makhene M, Nayak S, Pikaart-Tautges R, Roberts PC, Russell J, Sindall E, Albert J, Kunwar P, Makowski M, Anderson EJ, Bechnak A, Bower M, Camacho-Gonzalez AF, Collins M, Drobeniuc A, Edara VV, Edupuganti S, Floyd K, Gibson T, Ackerley CMG, Johnson B, Kamidani S, Kao C, Kelley C, Lai L, Macenczak H, McCullough MP, Peters E, Phadke VK, Rebolledo PA, Rostad CA, Rouphael N, Scherer E, Sherman A, Stephens K, Suthar MS, Teherani M, Traenkner J, Winston J, Yildirim I, Barr L, Benoit J, Carste B, Choe J, Dunstan M, Erolin R, Ffitch J, Fields C, Jackson LA, Kiniry E, Lasicka S, Lee S, Nguyen M, Pimienta S, Suyehira J, Witte M, Bennett H, Altaras NE, Carfi A, Hurley M, Leav B, Pajon R, Sun W, Zaks T, Coler RN, Larsen SE, Neuzil KM, Lindesmith LC, Martinez DR, Munt J, Mallory M, Edwards C, Baric RS, Berkowitz NM, Boritz EA, Carlton K, Corbett KS, Costner P, Creanga A, Doria-Rose NA, Douek DC, Flach B, Gaudinski M, Gordon I, Graham BS, Holman L, Ledgerwood JE, Leung K, Lin BC, Louder MK, Mascola JR, McDermott AB, Morabito KM, Novik L, O’Connell S, O’Dell S, Padilla M, Pegu A, Schmidt SD, Shi W, Swanson PA, II, Talana CA, Wang L, Widge AT, Yang ES, Zhang Y, Chappell JD, Denison MR, Hughes T, Lu X, Pruijssers AJ, Stevens LJ, Posavad CM, Gale M, Jr, Menachery V, Shi PY. 2021. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 373:1372–1377. doi:10.1126/science.abj4176.
    1. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lorks V, Sikorski J, Hilker R, Becker D, Eller AK, Grutzner J, Boesler C, Rosenbaum C, Kuhnle MC, Luxemburger U, Kemmer-Bruck A, Langer D, Bexon M, Bolte S, Kariko K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Tureci O. 2020. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586:594–599. doi:10.1038/s41586-020-2814-7.
    1. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC, Louder MK, O’Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd JM, Pessaint L, Van Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell TA, Cook A, Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng IT, Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-Jones G, Himansu S, Kong WP, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, Gaudinski MR, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M, Seder RA, Graham BS. 2020. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 383:1544–1555. doi:10.1056/NEJMoa2024671.
    1. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. 2021. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39:4423–4428. doi:10.1016/j.vaccine.2021.05.063.
    1. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27:1205–1211. doi:10.1038/s41591-021-01377-8.
    1. Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard K, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC. 2021. Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination. Nature doi:10.1038/s41586-021-04060-7.
    1. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. 2021. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371:eabf4063. doi:10.1126/science.abf4063.
    1. Sette A, Crotty S. 2021. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184:861–880. doi:10.1016/j.cell.2021.01.007.
    1. Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, Gruell H, Schlotz M, Ercanoglu MS, Stumpf R, Mayer P, Zehner M, Heger E, Johannis W, Horn C, Suarez I, Jung N, Salomon S, Eberhardt KA, Gathof B, Fatkenheuer G, Pfeifer N, Eggeling R, Augustin M, Lehmann C, Klein F. 2021. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe 29:917–929.e4. doi:10.1016/j.chom.2021.04.015.
    1. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, Gouma S, Kuri-Cervantes L, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Baxter AE, Oldridge DA, Giles JR, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Drapeau EM, Dougherty J, Long S, D’Andrea K, Hamilton JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, UPenn COVID Processing Unit, Frank I, Betts MR, Vella LA, Grifoni A, Weiskopf D, Sette A, Hensley SE, Davenport MP, Bates P, Luning Prak ET, Greenplate AR, Wherry EJ, Adamski S, Alam Z, Addison MM, Byrne KT, Chandra A, Descamps HC, Han N, Kaminskiy Y, Kammerman SC, Kim J, Greenplate AR, Hamilton JT, Markosyan N, Noll JH, Omran DK, Pattekar A, Perkey E, Prager EM, Pueschl D, Rennels A, Shah JB, Shilan JS, Wilhausen N, Vanderbeck AN. 2021. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science doi:10.1126/science.abm0829.
    1. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, Gouma S, Hicks P, Meng W, Rosenfeld AM, Dysinger S, Lundgreen KA, Kuri-Cervantes L, Adamski S, Hicks A, Korte S, Oldridge DA, Baxter AE, Giles JR, Weirick ME, McAllister CM, Dougherty J, Long S, D’Andrea K, Hamilton JT, Betts MR, Luning Prak ET, Bates P, Hensley SE, Greenplate AR, Wherry EJ. 2021. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci Immunol 6:eabi6950. doi:10.1126/sciimmunol.abi6950.
    1. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, Hoffmann HH, Barnes CO, Cipolla M, Ramos V, Oliveira TY, Cho A, Schmidt F, Da Silva J, Bednarski E, Aguado L, Yee J, Daga M, Turroja M, Millard KG, Jankovic M, Gazumyan A, Zhao Z, Rice CM, Bieniasz PD, Caskey M, Hatziioannou T, Nussenzweig MC. 2021. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595:426–431. doi:10.1038/s41586-021-03696-9.
    1. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, Cohen D, Muhsen K, Chodick G, Patalon T. 2021. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv doi:10.1101/2021.08.24.21262415.
    1. Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, DeSilva MB, Natarajan K, Yang DH, Rao S, Klein NP, Irving SA, Dixon BE, Dascomb K, Liao IC, Reynolds S, McEvoy C, Han J, Reese SE, Lewis N, Fadel WF, Grisel N, Murthy K, Ferdinands J, Kharbanda AB, Mitchell PK, Goddard K, Embi PJ, Arndorfer J, Raiyani C, Patel P, Rowley EA, Fireman B, Valvi NR, Griggs EP, Levy ME, Zerbo O, Porter RM, Birch RJ, Blanton L, Ball SW, Steffens A, Olson N, Williams J, Dickerson M, McMorrow M, Schrag SJ, Verani JR, Fry AM, Azziz-Baumgartner E, Barron M, Gaglani M, Thompson MG, Stenehjem E. 2021. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. MMWR Morb Mortal Wkly Rep 70:1539–1544. doi:10.15585/mmwr.mm7044e1.
    1. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan W-H, Chiu SS, Ko RLW, Chan KH, Cheng SMS, Perera RAPM, Cowling BJ, Poon LLM, Peiris M. 2021. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 12:63. doi:10.1038/s41467-020-20247-4.
    1. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, Goodwin B, Rubiro P, Sutherland A, Wang E, Frazier A, Ramirez SI, Rawlings SA, Smith DM, da Silva Antunes R, Peters B, Scheuermann RH, Weiskopf D, Crotty S, Grifoni A, Sette A. 2021. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep Med 2:100355. doi:10.1016/j.xcrm.2021.100355.
    1. Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, Norwood C, Nyhoff LE, Edara VV, Floyd K, De Rosa SC, Ahmed H, Whaley R, Patel SN, Prigmore B, Lemos MP, Davis CW, Furth S, O’Keefe JB, Gharpure MP, Gunisetty S, Stephens K, Antia R, Zarnitsyna VI, Stephens DS, Edupuganti S, Rouphael N, Anderson EJ, Mehta AK, Wrammert J, Suthar MS, Ahmed R, McElrath MJ. 2021. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med 2:100354. doi:10.1016/j.xcrm.2021.100354.
    1. Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, Ruddle NH, Galvani AP, Dornburg A. 2021. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe doi:10.1016/s2666-5247(21)00219-6.
    1. Romano CM, Felix AC, Paula AV, Jesus JG, Andrade PS, Candido D, Oliveira FM, Ribeiro AC, Silva FCD, Inemami M, Costa AA, Leal COD, Figueiredo WM, Pannuti CS, Souza WM, Faria NR, Sabino EC. 2021. SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State, Brazil. Rev Inst Med Trop Sao Paulo 63:e36. doi:10.1590/S1678-9946202163036.
    1. Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y, Shemer-Avni Y, Rosenberg E, Taube R. 2021. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe 29:522–528.e2. doi:10.1016/j.chom.2021.03.008.
    1. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for Covid-19 Vaccination. 2021. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 385:187–189. doi:10.1056/NEJMc2104974.
    1. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. 2021. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 385:661–662. doi:10.1056/NEJMc2108861.
    1. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, Walker AS, Peto TEA. 2021. The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission. medRxiv doi:10.1101/2021.09.28.21264260.
    1. Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte JM, Mak TM, Cui L, Kalimuddin S, Chia WN, Tan CW, Chai LYA, Tan SY, Zheng S, Lin RTP, Wang L, Leo YS, Lee VJ, Lye DC, Young BE. 2021. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv doi:10.1101/2021.07.28.21261295.
    1. Shamier MC, Tostmann A, Bogers S, de Wilde J, IJpelaar J, van der Kleij WA, de Jager H, Haagmans BL, Molenkamp R, Munnink BBO, van Rossum C, Rahamat-Langendoen J, van der Geest N, Bleeker-Rovers CP, Wertheim H, Koopmans MPG, GeurtsvanKessel CH. 2021. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers. medRxiv doi:10.1101/2021.08.20.21262158.
    1. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, Derqui-Fernandez N, Barnett JL, Whitfield MG, Varro R, Charlett A, Kundu R, Fenn J, Cutajar J, Quinn V, Conibear E, Barclay W, Freemont PS, Taylor GP, Ahmad S, Zambon M, Ferguson NM, Lalvani A, ATACCC Study Investigators. 2021. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis doi:10.1016/S1473-3099(21)00648-4.
    1. Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR. 2021. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Elife 10:e72619. doi:10.7554/eLife.72619.
    1. Saif LJ. 2020. Vaccines for COVID-19: perspectives, prospects, and challenges based on candidate SARS, MERS, and animal coronavirus vaccines. Eur Med J doi:10.33590/emj/200324.
    1. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, Huppert A. 2021. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 385:1393–1400. doi:10.1056/NEJMoa2114255.
    1. Bensouna I, Caudwell V, Kubab S, Acquaviva S, Pardon A, Vittoz N, Bozman DF, Hanafi L, Faucon AL, Housset P. 2021. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis doi:10.1053/j.ajkd.2021.08.005.
    1. Bertrand D, Hamzaoui M, Lemée V, Lamulle J, Laurent C, Etienne I, Lemoine M, Lebourg L, Hanoy M, Le Roy F, Nezam D, Farce F, Plantier JC, Boyer O, Guerrot D, Candon S. 2021. Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Kidney Int doi:10.1016/j.kint.2021.09.014.
    1. Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P, Clutterbuck EA, Davies S, Dejnirattisai W, Dold C, Ewer KJ, Folegatti PM, Fowler J, Hill AVS, Kerridge S, Minassian AM, Mongkolsapaya J, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Sheehan E, Smith H, Snape MD, Song R, Woods D, Screaton G, Gilbert SC, Voysey M, Pollard AJ, Lambe T, Oxford COVID Vaccine Trial group. 2021. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 398:981–990. doi:10.1016/S0140-6736(21)01699-8.
    1. Peled Y, Ram E, Lavee J, Segev A, Matezki S, Wieder-Finesod A, Halperin R, Mandelboim M, Indenbaum V, Levy I, Sternik L, Raanani E, Afek A, Kreiss Y, Lustig Y, Rahav G. 2021. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant doi:10.1016/j.healun.2021.08.010.
    1. Sadarangani M, Marchant A, Kollmann TR. 2021. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 21:475–484. doi:10.1038/s41577-021-00578-z.
    1. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobryzynski D, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek J, Islas CPD, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH. 2021. Heterologous SARS-CoV-2 booster vaccinations - preliminary report. medRxiv doi:10.1101/2021.10.10.21264827.
    1. Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, Wu C, Zhong Z, Wang F, Duan X, Tian S, Wu L, Liu Y, Luo Y, Chen Z, Li F, Li J, Yu X, Ren H, Liu L, Meng S, Yan J, Hu Z, Gao L, Gao GF. 2021. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 21:1107–1119. doi:10.1016/S1473-3099(21)00127-4.
    1. Yue L, Xie T, Yang T, Zhou J, Chen H, Zhu H, Li H, Xiang H, Wang J, Yang H, Zhao H, Wei X, Zhang Y, Xie Z. 2022. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine. J Med Virol 94:35–38. doi:10.1002/jmv.27334.
    1. Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S, Caillard S. 2021. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA 326:1063–1065. doi:10.1001/jama.2021.12339.
    1. Corbett KS, Gagne M, Wagner DA, O’Connell S, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham CD, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O’Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Yang ES, Wang L, Choe M, Boyoglu-Barnum S, Wei S, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, Seder RA. 2021. Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science doi:10.1126/science.abl8912.
    1. Deng Y, Li Y, Yang R, Tan W. 2021. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients. Cell Mol Immunol 18:2040–2041. doi:10.1038/s41423-021-00730-8.
    1. Hause AM, Baggs J, Gee J, Marquez P, Myers TR, Shimabukuro TT, Shay DK. 2021. Safety monitoring of an additional dose of COVID-19 vaccine - United States, August 12-September 19, 2021. MMWR Morb Mortal Wkly Rep 70:1379–1384. doi:10.15585/mmwr.mm7039e4.
    1. Shapiro Ben David S, Shamir-Stein N, Baruch Gez S, Lerner U, Rahamim-Cohen D, Ekka Zohar A. 2021. Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - a nationwide survey. Clin Immunol 232:108860. doi:10.1016/j.clim.2021.108860.
    1. Tam YH, Valkenburg SA, Perera R, Wong JHF, Fang VJ, Ng TWY, Kwong ASK, Tsui WWS, Ip DKM, Poon LLM, Chau CKV, Barr IG, Peiris JSM, Cowling BJ. 2018. Immune responses to twice-annual influenza vaccination in older adults in Hong Kong. Clin Infect Dis 66:904–912. doi:10.1093/cid/cix900.
    1. Anderson RM, May RM. 1985. Vaccination and herd immunity to infectious diseases. Nature 318:323–329. doi:10.1038/318323a0.
    1. Hethcote HW. 2000. The mathematics of infectious diseases. SIAM Rev 42:599–653. doi:10.1137/S0036144500371907.
    1. Dagpunar J. 2021. Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. medRxiv doi:10.1101/2021.06.03.21258293.
    1. Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC, Hatziioannou T, Bieniasz PD, Darnell RB. 2021. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 384:2212–2218. doi:10.1056/NEJMoa2105000.
    1. Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosi A. 2021. The importance and challenges of identifying SARS-CoV-2 reinfections. J Clin Microbiol 59:e02769-20. doi:10.1128/JCM.02769-20.
    1. Irons NJ, Raftery AE. 2021. Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys. Proc Natl Acad Sci USA 118:e2103272118. doi:10.1073/pnas.2103272118.
    1. Aschwanden C. 2021. Five reasons why COVID herd immunity is probably impossible. Nature 591:520–522. doi:10.1038/d41586-021-00728-2.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться